Calumet (NASDAQ:CLMT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Calumet (NASDAQ:CLMT – Free Report) from a hold rating to a buy rating in a research note published on Saturday,Wall Street Zen reports.

Other equities analysts also recently issued reports about the stock. UBS Group raised their price objective on shares of Calumet from $26.00 to $47.00 and gave the stock a “neutral” rating in a report on Tuesday, August 25th. Citigroup reiterated a “buy” rating on shares of Calumet in a research report on Monday, August 10th. Zacks Research cut shares of Calumet from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 3rd. HC Wainwright increased their price target on shares of Calumet from $60.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, September 2nd. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $57.00 price target on shares of Calumet in a research report on Wednesday, October 21st. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $54.75.

Check Out Our Latest Research Report on CLMT

Calumet Price Performance

Shares of CLMT stock opened at $31.96 on Friday. The stock has a market cap of $2.82 billion, a P/E ratio of -14.20, a price-to-earnings-growth ratio of 0.24 and a beta of 0.65. Calumet has a one year low of $17.85 and a one year high of $59.87. The stock has a fifty day moving average price of $51.43 and a 200 day moving average price of $39.40.

Calumet (NASDAQ:CLMT – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The oil and gas company reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $1.28. The firm had revenue of $1.68 billion for the quarter, compared to the consensus estimate of $1.34 billion. Calumet had a negative net margin of 3.73% and a negative return on equity of 32.93%. The business’s revenue was up 56.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.61 earnings per share. Equities research analysts anticipate that Calumet will post 3.09 EPS for the current year.

Institutional Trading of Calumet

Several institutional investors have recently bought and sold shares of CLMT. Farther Finance Advisors LLC raised its stake in Calumet by 8,950.0% during the third quarter. Farther Finance Advisors LLC now owns 905 shares of the oil and gas company’s stock worth $47,000 after acquiring an additional 895 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Calumet by 63.3% during the third quarter. GAMMA Investing LLC now owns 926 shares of the oil and gas company’s stock valued at $49,000 after acquiring an additional 359 shares during the period. Nykredit A S bought a new position in shares of Calumet during the second quarter valued at $57,000. Global Retirement Partners LLC bought a new position in shares of Calumet during the second quarter valued at $61,000. Finally, KBC Group NV bought a new position in shares of Calumet during the first quarter valued at $69,000. Institutional investors and hedge funds own 34.41% of the company’s stock.

Calumet Company Profile

(Get Free Report)

Calumet, Inc. is a U.S.-based producer of specialty hydrocarbon products, renewable fuels and conventional fuels. Its products serve customers in industries such as manufacturing, transportation, energy and consumer goods. The company’s specialty products include lubricating oils, solvents, waxes, petrolatums and asphalt. It also produces gasoline, diesel and other fuels, and through its Montana Renewables business makes lower-carbon fuels, including sustainable aviation fuel and renewable diesel.

Further Reading

Analyst Recommendations for Calumet (NASDAQ:CLMT)

Receive News & Ratings for Calumet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calumet and related companies with MarketBeat.com's FREE daily email newsletter.